The results have demonstrated that Gal-9 high-expressing ERCs restored liver function, ameliorated liver pathological damage, decreased the number of CD4+ and CD8+ cell, and inhibited Th1 and Th17 cell proliferation in the hepatitis mice. The gene discussed is CD8A; the disease is hepatitis A virus infection.